CN101257903A - 用于癌症治疗的包括二芳基脲化合物和PI3、AKT激酶或mTOR抑制剂(雷帕霉素类)的组合治疗 - Google Patents

用于癌症治疗的包括二芳基脲化合物和PI3、AKT激酶或mTOR抑制剂(雷帕霉素类)的组合治疗 Download PDF

Info

Publication number
CN101257903A
CN101257903A CNA2006800185177A CN200680018517A CN101257903A CN 101257903 A CN101257903 A CN 101257903A CN A2006800185177 A CNA2006800185177 A CN A2006800185177A CN 200680018517 A CN200680018517 A CN 200680018517A CN 101257903 A CN101257903 A CN 101257903A
Authority
CN
China
Prior art keywords
chemical compound
cancer
formula
combination
wortmannin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800185177A
Other languages
English (en)
Chinese (zh)
Inventor
U·朔伊林
I·伯纳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of CN101257903A publication Critical patent/CN101257903A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2006800185177A 2005-05-27 2006-05-13 用于癌症治疗的包括二芳基脲化合物和PI3、AKT激酶或mTOR抑制剂(雷帕霉素类)的组合治疗 Pending CN101257903A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05011477.6 2005-05-27
EP05011477 2005-05-27

Publications (1)

Publication Number Publication Date
CN101257903A true CN101257903A (zh) 2008-09-03

Family

ID=36636325

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800185177A Pending CN101257903A (zh) 2005-05-27 2006-05-13 用于癌症治疗的包括二芳基脲化合物和PI3、AKT激酶或mTOR抑制剂(雷帕霉素类)的组合治疗

Country Status (11)

Country Link
EP (1) EP1888067A1 (ja)
JP (1) JP2008542214A (ja)
KR (1) KR20080018908A (ja)
CN (1) CN101257903A (ja)
AU (1) AU2006251429A1 (ja)
BR (1) BRPI0610048A2 (ja)
CA (1) CA2609389A1 (ja)
IL (1) IL187508A0 (ja)
MX (1) MX2007014726A (ja)
RU (1) RU2007148266A (ja)
WO (1) WO2006125540A1 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102885814A (zh) * 2012-01-17 2013-01-23 湖南有色凯铂生物药业有限公司 一种化合物及其作为抗癌药物的应用
CN102940884A (zh) * 2012-11-19 2013-02-27 上海市肿瘤研究所 一种肝癌细胞的抑制剂及其在抑制肿瘤生长方面的应用
CN104892632A (zh) * 2015-06-03 2015-09-09 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
CN104906086A (zh) * 2015-06-24 2015-09-16 安徽四正医药科技有限公司 吲哚-3-甲醇、二吲哚甲烷及其衍生物用于治疗肾小球肾炎药物的应用
CN107205923A (zh) * 2014-12-17 2017-09-26 辉瑞大药厂 用于静脉内给药的pi3k/mtor‑抑制剂的制剂
CN115804844A (zh) * 2022-09-26 2023-03-17 郑州大学 靶向抑制pak4的抑制剂在制备肿瘤防治药剂中的应用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
JP4860474B2 (ja) 2003-05-20 2012-01-25 バイエル、ファーマシューテイカルズ、コーポレイション Ｐｄｇｆｒによって仲介される病気のためのジアリール尿素
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
UA93673C2 (ru) 2005-03-07 2011-03-10 Баер Шеринг Фарма Акциенгезельшафт Фармацевтическая композиция, которая содержит омега-карбоксиарилзамещенную дифенилмочевину, для лечения paka
WO2007068380A1 (en) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl urea for treating virus infections
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008089388A2 (en) * 2007-01-19 2008-07-24 Bayer Healthcare Llc Treatment of cancers having resistance to chemotherapeutic agents
CA2675980C (en) 2007-01-19 2016-06-21 Bayer Healthcare Llc Use of dast for treatment of cancers with acquired resistance to kit inhibitors
US7947723B2 (en) 2008-02-01 2011-05-24 Spelman College Synthesis and anti-proliferative effect of benzimidazole derivatives
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
US20110178137A1 (en) * 2008-06-25 2011-07-21 Bayer Schering Pharma Aktiengesellschaft Diaryl urea for treating heart failure
EP2356120B1 (en) * 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
US9421211B2 (en) 2009-05-28 2016-08-23 President And Fellows Of Harvard College N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation
CN102775385A (zh) * 2011-05-10 2012-11-14 湖南有色凯铂生物药业有限公司 N-取代苯基-n’-取代杂环脲类化合物及其作为抗癌药物的应用
CN102643229A (zh) * 2012-01-17 2012-08-22 湖南有色凯铂生物药业有限公司 N-((4-氯-3-三氟甲基)苯基)-n’-((2-氟-4-(2-氨基甲酰基)-4-吡啶基氧)苯基)脲及其作为抗癌药物的应用
US10420761B2 (en) 2013-03-15 2019-09-24 University Of Florida Research Foundation, Inc. Allosteric inhibitors of thymidylate synthase
US10835524B2 (en) 2015-06-24 2020-11-17 University Of Florida Research Foundation, Incorporated Compositions for the treatment of pancreatic cancer and uses thereof
KR102544163B1 (ko) * 2022-08-10 2023-06-16 주식회사 하이밸 소음저감형 유량 및 압력 조절용 감압밸브

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1663978T3 (da) * 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102885814A (zh) * 2012-01-17 2013-01-23 湖南有色凯铂生物药业有限公司 一种化合物及其作为抗癌药物的应用
CN102940884A (zh) * 2012-11-19 2013-02-27 上海市肿瘤研究所 一种肝癌细胞的抑制剂及其在抑制肿瘤生长方面的应用
CN107205923A (zh) * 2014-12-17 2017-09-26 辉瑞大药厂 用于静脉内给药的pi3k/mtor‑抑制剂的制剂
CN107205923B (zh) * 2014-12-17 2021-03-05 辉瑞大药厂 用于静脉内给药的pi3k/mtor-抑制剂的制剂
CN104892632A (zh) * 2015-06-03 2015-09-09 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
CN104906086A (zh) * 2015-06-24 2015-09-16 安徽四正医药科技有限公司 吲哚-3-甲醇、二吲哚甲烷及其衍生物用于治疗肾小球肾炎药物的应用
CN115804844A (zh) * 2022-09-26 2023-03-17 郑州大学 靶向抑制pak4的抑制剂在制备肿瘤防治药剂中的应用
CN115804844B (zh) * 2022-09-26 2024-05-10 郑州大学 靶向抑制pak4的抑制剂在制备肿瘤防治药剂中的应用

Also Published As

Publication number Publication date
WO2006125540A1 (en) 2006-11-30
IL187508A0 (en) 2008-06-05
JP2008542214A (ja) 2008-11-27
AU2006251429A1 (en) 2006-11-30
EP1888067A1 (en) 2008-02-20
RU2007148266A (ru) 2009-07-10
KR20080018908A (ko) 2008-02-28
CA2609389A1 (en) 2006-11-30
BRPI0610048A2 (pt) 2010-05-25
MX2007014726A (es) 2008-02-14

Similar Documents

Publication Publication Date Title
CN101257903A (zh) 用于癌症治疗的包括二芳基脲化合物和PI3、AKT激酶或mTOR抑制剂(雷帕霉素类)的组合治疗
US20090192127A1 (en) Combination therapy comprising a diaryl urea compound and a p13, akt kinase or mtor inhibitors (rapamycins) for cancer treatment
US20090306020A1 (en) Combination therapy comprising diaryl ureas for treating diseases
CN103874686B (zh) 用于抑制烟酰胺磷酸核糖基转移酶(nampt)的哌啶衍生物和组合物
RU2650895C2 (ru) Соединения замещенных пиразолонов и способы использования
TWI324066B (en) A pharmaceutical composition for inhibiting cell migration induced by an angiogenic factor
JP5820080B2 (ja) 三環系ＰＩ３Ｋ及び／又はｍＴＯＲ抑制剤
JP2022500384A (ja) 組み合わせ療法
CN101616917A (zh) 吡啶并[2,3-d]嘧啶以及它们作为激酶抑制剂的用途
CN105189486B (zh) 苯并呋喃酮与吲哚或氮杂吲哚偶合物及其制备与应用
CN105732591A (zh) 取代的哌嗪化合物及其使用方法和用途
CN106831824A (zh) 含萘啶酮结构的吡咯并吡啶类化合物及其应用
AU2019326768B2 (en) 2,6-bis(((1H-benzo[d]imidazol-2-yl)thio)methyl)pyridine and N2,N6-dibenzylpyridine-2,6-dicarboxamide derivatives and related compounds as phosphoinositide 3-kinase (PI3K) inhibitors for treating cancer
JP2010531322A (ja) アントラニルアミドピリジンウレア及びベンズアミド誘導体の相乗組合せ
CN103249411A (zh) 癌症治疗中的鬼臼苦素一水合物或多晶型物a
CN106810549B (zh) 含有二氢哒嗪结构的7-氮杂吲哚类化合物及其应用
CN101180055A (zh) 用于治疗疾病的包含二芳基脲的组合治疗
CN106795160B (zh) 取代的吲哚化合物及其使用方法和用途
CN109988169A (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
JP2014521640A (ja) 血管新生抑制作用を有する新規な化合物、その製造方法およびそれを含む薬学的組成物
GR1009604B (el) Μεθοδος προετοιμασιας και χρηση αναστολεων της 3-φωσφοινοσιδιτικης κινασης για καρκινικες νοσους
JP2022506289A (ja) インダゾールキナーゼ阻害剤及びその使用
CA3154278A1 (en) Phosphodiesterase inhibitors
CN109988171A (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN104788365A (zh) 异烟酰胺衍生物、其制备方法及应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080903